Leaflet MODERIBA 200mg film-coated tablets


Indicated for: chronic hepatitis C

Substance: ribavirin (antiviral)

ATC: J05AB04 (Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors)

Ribavirin is an antiviral medication used in the treatment of chronic hepatitis C and other severe viral infections. It works by inhibiting viral replication, reducing the viral load in the body.

The medication is taken orally, as directed by a doctor, usually in combination with other antiviral drugs such as interferon. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor the therapy's effectiveness.

Patients should be aware of potential side effects, such as anemia, fatigue, or skin irritation. It is important to inform the doctor of any unusual symptoms.

Common side effects include anemia, fatigue, and skin irritation. In rare cases, severe reactions such as depression or liver dysfunction may occur. Patients should be informed of these risks before use.

General data about MODERIBA 200mg

  • Substance: ribavirin
  • Date of last drug list: 01-05-2018
  • Commercial code: W61968001
  • Concentration: 200mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 168
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for ribavirin

Concentrations available for ribavirin

  • 200mg
  • 400mg
  • 40mg/ml
  • 600mg

Combinations with other substances